Cargando…
Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicar...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532985/ https://www.ncbi.nlm.nih.gov/pubmed/28381469 http://dx.doi.org/10.1161/JAHA.116.003918 |
_version_ | 1783253556423294976 |
---|---|
author | Miyagawa, Shigeru Domae, Keitaro Yoshikawa, Yasushi Fukushima, Satsuki Nakamura, Teruya Saito, Atsuhiro Sakata, Yasushi Hamada, Seiki Toda, Koichi Pak, Kyongsun Takeuchi, Masahiro Sawa, Yoshiki |
author_facet | Miyagawa, Shigeru Domae, Keitaro Yoshikawa, Yasushi Fukushima, Satsuki Nakamura, Teruya Saito, Atsuhiro Sakata, Yasushi Hamada, Seiki Toda, Koichi Pak, Kyongsun Takeuchi, Masahiro Sawa, Yoshiki |
author_sort | Miyagawa, Shigeru |
collection | PubMed |
description | BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicardial surface to maximize paracrine effects. This Phase I clinical trial tested whether transplanting autologous cell–sheets derived from skeletal muscle is feasible, safe, and effective for treating severe congestive heart failure. METHODS AND RESULTS: Fifteen ischemic cardiomyopathy patients and 12 patients with dilated cardiomyopathy, who were in New York Heart Association functional class II or III and had been treated with the maximum medical and/or interventional therapies available, were enrolled. Scaffold‐free cell sheets of 3 to 9×10(8) cells derived from autologous muscle were transplanted over the LV free wall via left thoracotomy, without additional interventional treatments. There were no procedure‐related major complications during follow‐up. The majority of the ischemic cardiomyopathy patients showed marked symptomatic improvement in New York Heart Association classification (pre: 2.9±0.5 versus 6 months: 2.1±0.4, P<0.01; 1 year: 1.9±0.3, P<0.01) and the Six‐Minute Walk Test with significant reduction of serum brain natriuretic peptide level (pre: 308±72 pg/mL versus 6 months: 191±56 versus 1 year: 182±46, P<0.05), pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary vein resistance, and left ventricular wall stress after transplantation instead of limited efficacy in dilated cardiomyopathy patients. CONCLUSIONS: Cell‐sheet transplantation as a sole therapy was feasible for treating cardiomyopathy. Promising results in the safety and functional recovery warrant further clinical follow‐up and larger studies to confirm this treatment's efficacy for severe congestive heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/english/. Unique identifier: UMIN000003273. |
format | Online Article Text |
id | pubmed-5532985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55329852017-08-14 Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy Miyagawa, Shigeru Domae, Keitaro Yoshikawa, Yasushi Fukushima, Satsuki Nakamura, Teruya Saito, Atsuhiro Sakata, Yasushi Hamada, Seiki Toda, Koichi Pak, Kyongsun Takeuchi, Masahiro Sawa, Yoshiki J Am Heart Assoc Original Research BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicardial surface to maximize paracrine effects. This Phase I clinical trial tested whether transplanting autologous cell–sheets derived from skeletal muscle is feasible, safe, and effective for treating severe congestive heart failure. METHODS AND RESULTS: Fifteen ischemic cardiomyopathy patients and 12 patients with dilated cardiomyopathy, who were in New York Heart Association functional class II or III and had been treated with the maximum medical and/or interventional therapies available, were enrolled. Scaffold‐free cell sheets of 3 to 9×10(8) cells derived from autologous muscle were transplanted over the LV free wall via left thoracotomy, without additional interventional treatments. There were no procedure‐related major complications during follow‐up. The majority of the ischemic cardiomyopathy patients showed marked symptomatic improvement in New York Heart Association classification (pre: 2.9±0.5 versus 6 months: 2.1±0.4, P<0.01; 1 year: 1.9±0.3, P<0.01) and the Six‐Minute Walk Test with significant reduction of serum brain natriuretic peptide level (pre: 308±72 pg/mL versus 6 months: 191±56 versus 1 year: 182±46, P<0.05), pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary vein resistance, and left ventricular wall stress after transplantation instead of limited efficacy in dilated cardiomyopathy patients. CONCLUSIONS: Cell‐sheet transplantation as a sole therapy was feasible for treating cardiomyopathy. Promising results in the safety and functional recovery warrant further clinical follow‐up and larger studies to confirm this treatment's efficacy for severe congestive heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/english/. Unique identifier: UMIN000003273. John Wiley and Sons Inc. 2017-04-05 /pmc/articles/PMC5532985/ /pubmed/28381469 http://dx.doi.org/10.1161/JAHA.116.003918 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Miyagawa, Shigeru Domae, Keitaro Yoshikawa, Yasushi Fukushima, Satsuki Nakamura, Teruya Saito, Atsuhiro Sakata, Yasushi Hamada, Seiki Toda, Koichi Pak, Kyongsun Takeuchi, Masahiro Sawa, Yoshiki Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title | Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title_full | Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title_fullStr | Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title_full_unstemmed | Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title_short | Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy |
title_sort | phase i clinical trial of autologous stem cell–sheet transplantation therapy for treating cardiomyopathy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532985/ https://www.ncbi.nlm.nih.gov/pubmed/28381469 http://dx.doi.org/10.1161/JAHA.116.003918 |
work_keys_str_mv | AT miyagawashigeru phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT domaekeitaro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT yoshikawayasushi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT fukushimasatsuki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT nakamurateruya phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT saitoatsuhiro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT sakatayasushi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT hamadaseiki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT todakoichi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT pakkyongsun phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT takeuchimasahiro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy AT sawayoshiki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy |